Acorda Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:01 pm EST
Share
Acorda Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 27.72 million compared to USD 33.51 million a year ago. Net loss was USD 8.89 million compared to USD 13.85 million a year ago. Basic loss per share from continuing operations was USD 7.16 compared to USD 11.17 a year ago. Diluted loss per share from continuing operations was USD 7.16 compared to USD 11.17 a year ago.
For the nine months, revenue was USD 79.65 million compared to USD 87.1 million a year ago. Net loss was USD 35.09 million compared to USD 85.06 million a year ago. Basic loss per share from continuing operations was USD 28.25 compared to USD 97.66 a year ago. Diluted loss per share from continuing operations was USD 28.25 compared to USD 97.66 a year ago.
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinsonâs disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.